Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
| ▸ | USP19 | O94966 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17396676 | 0.98 | L3MBTL1 (0.36) | L3MBTL1KMT2AF10KDM4ESMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL28374959 | 0.90 | PKM (0.38) | L3MBTL1KMT2AF10KDM4ESMN1; SMN2 | |
| SCHEMBL8381615 | 0.84 | SMN1; SMN2 (0.38) | F10KDM4ESMN1; SMN2BRD4KAT2B | |
| SCHEMBL853682 | 0.84 | GSK3B (0.42) | L3MBTL1KMT2AALDH1A1TSHRTDP1 | |
| Hydrochloric Acid SCHEMBL4133179 | 0.83 | GSK3A (0.41) | L3MBTL1KMT2ALMNAALDH1A1TSHR | |
| SCHEMBL4388001 | 0.83 | PLA2G10 (0.43) | KMT2AF10KDM4EUSP19ALDH1A1 | |
| SCHEMBL21520072 | 0.81 | TSHR (0.40) | F10SMN1; SMN2BRD4KAT2BLMNA | |
| SCHEMBL15244381 | 0.80 | F10 (0.40) | KMT2AF10CHRM3USP19LMNA | |
| SCHEMBL3833137 | 0.79 | TSHR (0.44) | KMT2AF10KDM4EUSP19LMNA | |
| SCHEMBL18743866 | 0.77 | F10 (0.35) | F10USP19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110563706-B | MDM2 protein degradation targeting chimera and preparation method and application thereof | 中国人民解放军第二军医大学 | 2021-11-09 | — | — | CN | claimed |
| CN-110563706-A | MDM2 protein degradation targeting chimera and preparation method and application thereof | 中国人民解放军第二军医大学 | 2019-12-13 | — | — | CN | claimed |
| EP-4159727-B1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12415796-B2 | Inhibitors of (αv)(β6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20240327378-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2024-10-03 | — | — | US | disclosed |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| CN-116283977-A | Inhibitors of αvβ6 integrin | 莫菲克医疗股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-110573499-B | Inhibitors of αvβ6 integrin | 莫菲克医疗股份有限公司 | 2023-04-21 | — | — | CN | disclosed |
| US-20230124815-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-04-20 | — | — | US | disclosed |
| US-8669249-B2 | Poly (ADP-ribose) polymerase (PARP) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-11 | — | — | US | disclosed |
| US-20120094992-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2415767-A1 | Poly (ADP-ribose) Polymerase (PARP) Inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010111626-A2 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | WO | disclosed |
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| CN-101605798-A | Imidazothiazole derivative | DAIICHI SANKYO CO LTD (JP) | 2009-12-16 | — | — | CN | disclosed |
| CN-1886376-A | Pyridine compounds as dipeptidyl dipeptidase-IV inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-12-27 | — | — | CN | disclosed |
| US-5908843-A | Piperazine compounds as fibrinogen inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1999-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327378-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | L3MBTL1 1265/4885KMT2A 3926/4885F10 1243/4885 |
| US-20090312310-A1 | Imidazothiazole derivatives | TP53, MDM2, TP53BP1 | L3MBTL1 299/4885KMT2A 1259/4885F10 3925/4885 |
| US-20230124815-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | L3MBTL1 1762/4885KMT2A 2651/4885F10 4315/4885 |
| US-12415796-B2 | Inhibitors of (αv)(β6) integrin | ITGB6, ITGA6, ITGAV | L3MBTL1 1387/4885KMT2A 4109/4885F10 1194/4885 |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | L3MBTL1 1323/4885KMT2A 4013/4885F10 1179/4885 |
| US-20120094992-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP3 | L3MBTL1 3475/4885KMT2A 1732/4885F10 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.